Tuesday, May 21, 2024

6:00-7:30p.m

 

Cardiovascular diseases are still among the leading causes of mortality and morbidity in the world today. To address this critical issue, the past decade has witnessed a surge in cardiovascular outcome trials focused on evaluating the cardiovascular safety and efficacy of various drugs. One class of drugs that has gained significant attention is the glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Please join us to hear Dr. Herbert D. Aronow discuss the novel cardiovascular applications of GLP-1 RA drugs in the assessment and treatment of cardiovascular diseases.

MORE INFORMATION AND REGISTER >>

Learning Objectives

Upon completion of this conference, participants should be better able to:

• Evaluate GLP-1 RA mediated cardiovascular risk factor modification.
• Assess reduction in atherothrombotic event risk through GLP-1 RA.
• Explore potential novel cardiovascular applications for GLP-1 RA.